Best of ASCO - 2014 Annual Meeting

 

Welcome

Cellular Immunotherapy

Developmental Therapeutics—Immunotherapy

2017 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A combined local treatment with anti-PD-1 antibody and bone marrow derived dendritic cells after x-ray irradiation to subcutaneous melanoma in a murine model.

Yuzi Wang

e14541

A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types.

Bikash Verma

TPS3093

A phase 1b/2 study of CD30-specific chimeric antigen receptor T-cell (CAR-T) therapy in combination with bendamustine in patients with CD30+ Hodgkin and non-Hodgkin lymphoma.

Steven I. Park

TPS3095

A phase I single arm, open label clinical trial evaluating safety of MAGE-A10c796T in subjects with advanced or metastatic head and neck, melanoma, or urothelial tumors (NCT02989064).

David S. Hong

TPS3098

A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC).

Bo Zhai

3049

A phase I study of the bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.

Martin Wermke

TPS3091

A phase I/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers.

Christian S. Hinrichs

3009

A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).

Kunle Odunsi

TPS3094

A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743).

Sandra P. D'Angelo

TPS3097

Active specific immunotherapy for lethal canine hemangiosarcoma: A model system for the treatment of angiosarcoma with curative intent.

William Karl Decker

e14539

Anti-PD-1 monoclonal antibody combined CD3-retronectin activated T cell in heavy-treated renal cell cancer.

Lingdi Zhao

3047

Antitumor effect of a whole tumor cell vaccine expressing human fibroblast activation protein in murine tumor models.

Meihua Chen

e14542

Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab.

Kelly Garneski Paulson

3044

CD133-redirected chimeric antigen receptor engineered autologous T-cell treatment in patients with advanced and metastatic malignancies.

Yao Wang

3042

Chimeric antigen receptor (CAR) T cells genetically engineered to deliver IL-12 to the tumor microenvironment in ovarian cancer.

Oladapo O. Yeku

3050

Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells.

Cameron John Turtle

3020

Defining an allogeneic CAR-T approach by shRNA-mediated knockdown of the T-cell receptor.

David Suhy

e14551

Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

Frank (Xiaohu) Fan

LBA3001

Effect of BL-8040, high-affinity CXCR4 antagonist, on T-cell infiltration, tumor growth, and synergy with immunomodulatory agents.

Michal Abraham

e14544

Effect of chimeric antigen receptor (CAR) T cells on clonal expansion of endogenous non-CAR T cells in patients (pts) with advanced solid cancer.

Rebecca H Kim

3011

Efficacy of CD19-targeted chimeric antigen receptor T cells in the treatment of relapsed extramedullary B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL).

Yongxian Hu

e14549

Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy.

Amod Sarnaik

3045

Evaluating the reversible control of an engineered CAR T cell ON-switch.

Amy Gilbert

e14550

Feasibility of cancer vaccine therapy using dendritic cells generated from induced pluripotent stem cells expressing carcinoembryonic antigen.

Toshiyasu Ojima

e14538

Feasible and efficient identification of neoantigens for personalized cancer immunotherapy in advanced refractory epithelial cancer patients.

Fangjun Chen

3046

First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.

Jesus G. Berdeja

3010

High-fidelity genome editing using NextGEN CRISPR (Clo51-dCas9) system for the production of allogeneic CAR-T cells.

Xinxin Wang

3048

Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma (NCT01343043).

Crystal Mackall

3000

Phase 1 study of intraperitoneal infusion of autologous monocytes with peginterferon alfa-2b and interferon gamma-1b in women with recurrent or refractory ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Ana Tablante Nunes

TPS3092

Preclinical development of tumor-infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma and the potential benefit of anti-CD137 stimulation.

Morten Nielsen

e14545

Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody.

Yihong Yao

e14548

The anti-tumour immune response after radiofrequency ablation of colorectal cancer.

Katia Lemdani

e14540

The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).

Shannon L. Maude

103

Tumor-penetrating peptide iRGD conjugation effectively potentiates intratumor T cell infiltration.

Naiqing Ding

e14543

Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577).

Ben C. Creelan

TPS3096

Utilizing IL-7 to generate melanoma antigen T cell receptor-modified cells for adoptive transfer in the absence of activation.

Siao-Yi Wang

e14552